ClinicalTrials.gg
CompletedNCT04143750Updated Apr 3, 2020

The Mass Balance and Biotransformation of [14C] Vicagrel in Healthy Man

A Phase 1 interventional study of [14C]Vicagrel in Healthy Male Adult, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-03.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This study was designed to evaluate the mass balance and biotransformation after single-dose of [14C]Vicagrel orally in Chinese healthy male volunteers, revealing the overall pharmacokinetic characteristics of vicagrel in humans, and providing a reference for the rational administration.

02

Conditions studied

  • Healthy Male Adult
03

In context

Lead sponsor

Jiangsu vcare pharmaceutical technology co., LTD is the lead sponsor of 35 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A healthy male adult.
  • Age is between 18 and 45, inclusive.
  • is between 19 and 26, inclusive.
  • Voluntarily to provide form.
  • Willing and able to communicate with investigators and complete the trial according to clinical trial protocol.

Exclusion criteria

Exclusion Criteria:

  • Any abnormal and clinical significant findings to physic exam, vital sign, , X-ray exam for chest, laboratory exam including blood biochemical, blood routine, blood coagulation, urine routine, routine stool plus occult blood and thyroid stimulating hormone, and so on.
  • A positive examination result of /HBeAg, antibody and treponema pallidum antibody.
  • Volunteers who take any medicines including OTC, hormone and/or alternative medicines such as medicated diets, Chinese herbal medicines, hemostatics or supplements within 14 days before the screening.
  • Volunteers have clinical product administration or clinical trial participation within 3 months before the screening.
  • Any history of clinical serious disease, or presence illness/condition that, in the opinion of the investigator, would jeopardize the study results, including but not limited to the circulatory system, endocrine system, nervous system, digestive system, urinary system or history of blood, immune, mental and metabolic diseases.
  • History of organic heart disease, heart failure, myocardial infarction, angina pectoris, unexplained arrhythmia, torsade ventricular tachycardia, ventricular tachycardia, syndrome, or QT prolongation Symptoms and family history ,indicated by genetic evidence or sudden death of a close relative due to cardiac conditions at a young age.
  • Volunteers or their immediate family have coagulopathy, coagulative/hemorrhagic disease ,such as hemophilia, gastrointestinal bleeding, cyanosis, coagulative /hemorrhagic symptoms ,such as hematemesis, melena, severe or recurrent epistaxis, hemoptysis, obvious hematuria or intracranial hemorrhage, coagulative/hemorrhagic family history, suspected vascular malformations, such as aneurysm or early onset stroke, CVA \< 65 years old, bleeding tendency ,such as repeated bleeding gums, or previous active pathological bleeding.
  • Current or recent (\<6 months) disease of dyspepsia, esophageal reflux, stomach bleeding, peptic ulcer, often heartburn over one times every week or any surgery that may affect drug absorption , such as cholecystectomy.
  • Major surgery or surgical incision did not completely heal within 6 months before the screening. Major surgery includes, but is not limited to, any volunteer with significant bleeding risk, prolonged general anesthesia, incision of a or significant traumatic injury.
  • Ecchymoses were detected in the skin during physical examination.
  • The (PT) and/or activated partial thromboplastin time (APTT) exceeds the , or the hematocrit (HCT) or count (PLT) is out of the normal range.
  • Volunteers who are allergic to drugs, the same type of product ,such as clopidogrel, ticagrelor, etc., pharmaceutical , alcohol, food ingredients. Or who has special requirements for diet and cannot comply with the required diet.
  • Suffering acne or perianal disease in blood in the stool or regularly.
  • Volunteers have habitual constipation, diarrhea, irritable bowel syndrome or inflammatory bowel disease.
  • Volunteers are alcoholism, often drinking in six months before screening which means more than 14 units of alcohol every week, or the alcohol breath test result is positive in screening. One unit alcohol equals 360 mL of beer, 45 mL of 40% alcohol or 150 mL of wine.
  • Volunteers have daily smoking exceeds 5 cigarettes in three months before screening, or habitual use of nicotine products, and can not be withdrawn during the trial.
  • Abusing drug, using soft drugs such as marijuana three months prior to screening, using hard drugs such as cocaine, amphetamine, phencyclidine, etc. one year prior to screening; or urine test for drugs is positive in screeing.
  • Volunteers have habitual drinking of grapefruit juice, excessive tea, coffee and/or caffeinated beverages, and who can not be abstained during the trial.
  • Volunteers who have to work in radioactive conditions in long time, participated in radio-labeled drug clinical trial or had significant radioactive exposure within one year before the trial, more than 2 times of chest/abdominal CT, or more than 3 times of different types of X-ray exam.
  • Volunteer and their spouse who have a birth plan or who are unwilling to take strict contraceptive measures such as condoms, contraceptive sponges, contraceptive gels, contraceptive film, intrauterine device, contraceptive for oral and injection, subcutaneous implant, etc., during the trial or in the future one year after the trial.
  • Volunteers, who have had blood loss/donation up to 400 mL within 3 months before the screening, or received blood transfusion within 1 month.
  • Volunteers are not suitable for this clinical trial, in the opinions of investigators.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]Vicagrel

    Drug: [14C]Vicagrel

Interventions

  • Take a suspension of 20 mg vicagrel ,containing about 120 μCi \[14C\]Vicagrel, in fasting within 5 minutes

06

What researchers measure

Primary outcomes

  1. Total radioactive datas in blood

    Total radioactive distribution and pharmacokinetics in blood and plasma

    Time frame: from 0 hour to 240 hours after administration

  2. Total radioactive datas in excreta

    Total radioactive distribution and pharmacokinetics in urine and feces; the main routes of \[14C\]Vicagrel excretion in human

    Time frame: from 0 hour to 240 hours after administration

  3. Peak Plasma Concentration (Cmax)

    Determine the Cmax of Vicagrel metabolites M3, M9-2, M15-1 and M15-2 in plasma

    Time frame: from 0 hour to 240 hours after administration

  4. Area under the plasma concentration versus time curve (AUC)

    Determine the AUC of Vicagrel metabolites M3, M9-2, M15-1 and M15-2 in plasma

    Time frame: from 0 hour to 240 hours after administration

  5. Time of Peak Plasma Concentration(Tmax)

    Determine the Tmax of Vicagrel metabolites M3, M9-2, M15-1 and M15-2 in plasma

    Time frame: from 0 hour to 240 hours after administration

  6. Drug half-life in plasma(t1/2)

    Determine the T1/2 of Vicagrel metabolites M3, M9-2, M15-1 and M15-2 in plasma

    Time frame: from 0 hour to 240 hours after administration

  7. Mean Residence Time (MRT)

    Determine the MRT of Vicagrel metabolites M3, M9-2, M15-1 and M15-2 in plasma

    Time frame: from 0 hour to 240 hours after administration

  8. Numbers of Vicagrel Metabolites

    Detect Vicagrel Metabolites in blood, feces and urines as much as possible to clear the main routes of biotransformation

    Time frame: from 0 hour to 240 hours after administration

Secondary outcomes

  1. Adverse Events

    Review the relationship between investigational products and all the abnormal and clinically significant findings

    Time frame: through the completion of study, an average of 2 months

07

Study locations

1 site
  • The First Affiliated Hospital of Suzhou University
    Suzhou, Jiangsu, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Dec 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2019
First posted
Oct 29, 2019
StartActual
Nov 11, 2019
Primary completionActual
Dec 29, 2019
CompletionActual
Jan 14, 2020
Last update
Apr 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04143750
Responsible party
Sponsor
First posted
Oct 29, 2019
Start date
Nov 11, 2019
Primary completion
Dec 29, 2019
Completion
Jan 14, 2020
Last update
Apr 3, 2020

Study contacts

Liyan Miao, PhD
principal investigator · First Affiliated Hospital of Suzhou Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sumecigrel

Start the discussion